NASCIMBENI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.397
AS - Asia 4.545
EU - Europa 4.183
SA - Sud America 784
AF - Africa 129
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 4
Totale 19.056
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.240
SG - Singapore 1.420
CN - Cina 1.155
GB - Regno Unito 1.032
IT - Italia 920
HK - Hong Kong 635
BR - Brasile 574
VN - Vietnam 510
FI - Finlandia 359
DE - Germania 355
SE - Svezia 346
PL - Polonia 264
FR - Francia 208
RU - Federazione Russa 179
IN - India 133
KR - Corea 130
TR - Turchia 113
UA - Ucraina 113
AR - Argentina 73
BG - Bulgaria 71
NL - Olanda 71
ID - Indonesia 70
CA - Canada 64
BD - Bangladesh 59
MX - Messico 51
JP - Giappone 48
IQ - Iraq 45
ZA - Sudafrica 41
ES - Italia 37
EC - Ecuador 32
LT - Lituania 31
IE - Irlanda 30
PK - Pakistan 30
VE - Venezuela 27
AE - Emirati Arabi Uniti 25
BE - Belgio 25
EG - Egitto 23
CO - Colombia 22
UZ - Uzbekistan 21
RO - Romania 20
SA - Arabia Saudita 20
GR - Grecia 18
AT - Austria 17
CH - Svizzera 17
JO - Giordania 16
MY - Malesia 15
PE - Perù 15
CZ - Repubblica Ceca 14
PH - Filippine 13
PY - Paraguay 13
AU - Australia 12
CL - Cile 12
DZ - Algeria 12
KE - Kenya 11
MA - Marocco 10
NP - Nepal 9
SI - Slovenia 9
TN - Tunisia 9
TW - Taiwan 9
UY - Uruguay 9
IL - Israele 8
JM - Giamaica 8
KZ - Kazakistan 8
RS - Serbia 8
AZ - Azerbaigian 7
BO - Bolivia 7
ET - Etiopia 6
HN - Honduras 6
IR - Iran 6
KG - Kirghizistan 6
MK - Macedonia 6
EE - Estonia 5
PT - Portogallo 5
QA - Qatar 5
AL - Albania 4
BY - Bielorussia 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
OM - Oman 4
SV - El Salvador 4
BZ - Belize 3
GE - Georgia 3
LB - Libano 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CG - Congo 2
CI - Costa d'Avorio 2
CY - Cipro 2
EU - Europa 2
GH - Ghana 2
HR - Croazia 2
KW - Kuwait 2
LV - Lettonia 2
MM - Myanmar 2
MT - Malta 2
NG - Nigeria 2
NI - Nicaragua 2
Totale 19.022
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Ashburn 962
Singapore 914
Santa Clara 829
Southend 620
Hong Kong 614
Woodbridge 557
Chandler 470
Houston 451
Seattle 451
Wilmington 402
San Jose 382
Cambridge 348
Hefei 330
Ann Arbor 317
Helsinki 317
Nyköping 268
Warsaw 256
Dearborn 236
Beijing 221
London 211
Los Angeles 154
Ho Chi Minh City 153
Council Bluffs 146
New York 144
Hanoi 124
Modena 124
Jacksonville 120
Seoul 107
Chicago 103
The Dalles 87
San Diego 82
Lauterbourg 70
Sofia 67
Milan 66
Princeton 65
Eugene 62
Rome 57
Munich 56
Izmir 54
São Paulo 53
Jakarta 50
Moscow 48
Shanghai 48
Buffalo 44
Dallas 42
Tokyo 39
Denver 38
Salt Lake City 37
Orem 34
Frankfurt am Main 32
Da Nang 28
Johannesburg 27
Chennai 26
Haiphong 26
Poplar 26
Bremen 25
Dublin 25
Manchester 25
Nuremberg 25
Redwood City 24
Bologna 23
Fremont 22
Toronto 22
Biên Hòa 21
Tampa 21
Atlanta 20
Brussels 20
Boardman 19
Columbus 19
Paris 19
Rio de Janeiro 19
Tashkent 19
Amsterdam 18
Montreal 18
Redondo Beach 18
Mexico City 17
Phoenix 17
Reggio Emilia 17
San Mateo 17
Schiffdorf 17
Stockholm 17
Baghdad 16
Brooklyn 16
Dong Ket 16
Mumbai 16
Padova 16
Falls Church 15
Timisoara 15
Athens 14
Naples 14
Norwalk 14
Parma 14
Kent 13
Nanjing 13
Palermo 13
Turku 13
Amman 12
Boston 12
Buenos Aires 12
Totale 13.475
Salva come PNG Salva come JPEG
Nome #
Terapia antialadosteronica e prevenzione della cardiomiopatia cirrotica 699
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 524
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 474
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis 372
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis 349
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 349
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk 348
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV 325
ANTIALDOSTERONE THERAPY IN LIVER CIRRHOSIS: A ROLE FOR PREVENTION OF CIRROTHIC CARDIOMIOPATHY? 312
Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes 307
Drugs and acute porphyrias: reasons for a hazardous relationship 306
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 300
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease 300
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 299
Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? 298
Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? 298
Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomeres involvement on line pubblication 03-Oct-2012Hepatology- 297
A critical appraisal of the use of ultrasound in hepatic steatosis 287
Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy 286
Nonalcoholic fatty liver disease: Evolving paradigms 280
From NAFLD in clinical practice to answers from guidelines. 276
Clinical relevance of liver histopathology and different histological classifications of NASH in adults 273
MTHFR C677T polymorhism and hyperhomocysteinemia in patients with liver cirrhosis complicated by portal vein thrombosis and hepatocellular carcinoma 271
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 269
Alcohol and Steatosis: The Japanese Paradox 268
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 267
Role of Multidrug-Resistance Protein 2 in coproporphyrin transport: results from experimental studies in bile fistula rat models 266
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 266
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 264
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? 264
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases 258
Association between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis 257
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 254
Hypothyroidism and nonalcoholic fatty liver disease - A chance association? 248
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy 247
Global multi-stakeholder endorsement of the MAFLD definition 246
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 242
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? 239
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease 239
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 236
Insulin resistance in advanced liver cirrhosis : the role of liver dysfunction and the “dissociated” effect on glucose versus lipid and amino acid metabolism 224
Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: The “Musketeer” in the spotlight 223
Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk? 216
Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity? 208
Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? 205
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease 202
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications 201
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? 200
Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? 195
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? 195
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans 187
The genetic basis of Insulin resistance. A brief review 184
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease 183
Hyperferritinemia and diagnosis of type 1 Gaucher disease 180
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 177
Sex Differences in NAFLD: State of the Art and Identification of Research Gaps 177
Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements 174
Non-alcoholic fatty liver disease: Diagnosis and investigation 169
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk 165
Frailty after Liver Transplantation: A Complex Unexplored Issue 164
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment 163
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 162
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry 159
Hepatic and extrahepatic malignancies in NAFLD 158
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group 157
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist 156
Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases 148
Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation? 144
Colon cancer in a 12-year-old girl with hypertriglyceridemia 142
Lipidomic profiling of MASLD: identifying lipid biomarkers for detection and stratification of disease severity 140
Metabolic Disorders in Liver Transplant Recipients: The State of the Art 131
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia 129
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study 129
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 128
Identifying lipid patterns through lipidomic profiling for MASLD detection and severity stratification 125
Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease 119
Liver transplantation and nonalcoholic steatohepatitis: the state of the art 118
Mapping the lipid landscape of MASLD: insights into disease progression through lipidomic patterns 108
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease 100
Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease 99
Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN) 91
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease 90
Splenomegaly: Dare to think rare 83
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric Group 61
Diagnosi e storia naturale della steatosi epatica non alcolica. Performance e limiti delle tecniche diagnostiche invasive e non invasive e risultati del follow-up a lungo termine delle cirrosi criptogenetiche. 61
Identifying possible homozygous familial hypercholesterolemia patients: An Italian experts' opinion 61
Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study 52
Totale 19.203
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021441 0 0 0 0 0 0 0 0 0 182 164 95
2021/20221.340 102 118 65 77 83 112 45 53 163 149 247 126
2022/20231.407 133 173 140 123 150 176 27 149 175 17 66 78
2023/2024829 34 53 79 69 162 75 56 82 22 23 56 118
2024/20253.350 82 46 99 191 613 447 319 215 342 201 357 438
2025/20266.829 440 279 583 856 1.108 766 977 373 792 655 0 0
Totale 19.203